Prof. MD. Erdinç Nayır

Education & Training

• 1997–2003 – Fırat University Faculty of Medicine – Medical Education

• 2004–2010 – Mersin University Faculty of Medicine – Internal Medicine Residency

• 2011–2014 – Mersin University Faculty of Medicine – Medical Oncology Fellowship

Courses & Certifications

• Advanced Training Course for Research Assistants, Mersin, 2009

• Advanced Clinical Trials School, Cyprus, 2012

• Statistical Analysis Training, Mersin, 2013

Professional Memberships

• Member, Turkish Society of Medical Oncology (TTOD)

• Member, European Society for Medical Oncology (ESMO)

• Member, TTOD Press and Public Relations Committee (2015–2017)

• Member, Medical Oncology Group (TOG)

• Vice Chair, TOG Epidemiology and Prevention Group (2014–Present)

• Vice Chair, TOG Young Researchers Group (2015–Present)

Awards

• Best Oral Presentation Award (2006):
  Do MTHFR polymorphisms lead to progression of steatosis and fibrosis in patients with chronic hepatitis C? – Turkish Gastroenterology Association

• Third Prize, Best Poster Presentation (2012):
  Clinical, pathological, and treatment response analysis of head and neck non-Hodgkin lymphomas – Lymphoma Myeloma Association

• Third Prize, Best Study – 6th TTOK (2016):
  Can elevated hemoglobin during tyrosine kinase inhibitor use in metastatic renal cell carcinoma be a positive predictive marker? – Turkish Society of Medical Oncology

• Best Oral Presentation Award – 6th TTOK (2016):
  Knowledge and attitudes regarding consolidation radiotherapy in NHL and HL patients with complete response on post-chemotherapy PET-CT – Turkish Society of Medical Oncology

• Second Prize, Best Oral Presentation – 11th Multidisciplinary Neuro-Oncology Symposium (2017):
  Relationship between irinotecan/bevacizumab treatment and NLR – Neuro-Oncology Association

• Best Oral Presentation Award – 22nd National Cancer Congress (2017):
  Comparative study of paclitaxel + carboplatin vs. cisplatin + etoposide – Turkish Society of Medical Oncology

• Third Prize, Journal of Oncological Sciences (2018):
  Investigation of antitumoral activity in anaplastic thyroid cancer cell culture – Turkish Society of Medical Oncology

A. Articles Published in Science Citation Index (SCI) and Science Citation Index Expanded (SCI-E) Journals

• A1. Sezgin O, Altintas E, Nayir E, Ucbilek E. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Helicobacter. 2007;12(6):629-632.

• A2. Akbay E, Muslu N, Nayir E, Ozhan O, Kiykim A. Serum retinol binding protein 4 level is related with renal functions in Type 2 diabetes. Journal of Endocrinological Investigation. 2010;33(10):725-729.

• A3. Abali H, Celik I, Karaca B, Turna H, Saglam EK, Akman T, Oztop I, Coskun HS, Turhal NS, Sezer A, Nayır E et al. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study. JBUON. 2015;20(4):1137-1141.

• A4. Nayır E, Ata A, Arican A. Do medical oncologists and cancer patients care about treatment cost of systemic anticancer therapy? JBUON. 2015;20(6):1606-1611.

• A5. Unlu A, Nayır E, Kırca O, Ozdogan M. Ganoderma lucidum (reishi mushroom) and cancer. JBUON. 2016;21(4):792-798.

• A6. Unlu A, Nayir E, Kalenderoglu MD, Kirca O, Ozdogan M. Curcumin (Turmeric) and cancer. JBUON. 2016;21(5):1050-1060.

• A7. Nayir E, Tanriverdi O, Karakas Y, Kilickap S, Turhal NS, Avci N, Okutur K, Koca D, Erdem D, Abali H, Yamac D, Bilir C, Kacan T. Tendency of cancer patients, and their relatives, to use internet for health-related searches: Turkish Oncology Group (TOG) Study. JBUON. 2016;21(3):714-719.

• A8. Eras N, Nayir E, Arican A, Bahar L, Guler M, Akbas E. TS 1494del6 polymorphism and increased risk of developing breast cancer. International Journal of Clinical and Experimental Medicine. 2016;9(6):11756-11763.

• A9. Nayir E, Koyuncu MB, Esin E, Turker I, Tanriverdi O, Uysal M, Er O, Demir A, Akman TT, Pilanci KN, Paydas S, Kocar M, Saip P, Kilickap S, Turhal S, Kacan T. Attitudes of cancer patients after diagnosis: How cancer affects social life? (Turkish Oncology Group Study). JBUON. 2016;21(5).

• A10. Unlu A, Nayir E, Kirca O, Ay H, Ozdogan M. Ginseng and cancer. JBUON. 2016;21(6):1383-1387.

• A11. Bilir C, Yıldız I, Bilici A, Ucar M, Berk V, Yıldız Y, Yazıcı O, Imamoglu GI, Karadurmus N, Pilancı KN, Arpacı E, Tanrıverdi O, Karcı E, Temiz S, Nayir E, Oktay E, Dal P, Petekkaya I, Varim C, Cinemre H. Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. Cancer Investigation. 2017;35(4):248-255.

B. Articles Published in Emerging Sources Citation Index (ESCI) Journals

• B1. Akca M, Ata A, Nayir E, Erdogdu S, Arican A. Impact of Surgery Type on Quality of Life in Breast Cancer Patients. Journal of Breast Health. 2014;10:222-228.

• B2. Nayır E, Ata A, Erdoğdu S, Arıcan A. Türkiye’de onkoloji alanındaki klinik araştırmaların durumu. Turkish Journal of Oncology. 2014;29(4):181-182.

• B3. Nayır E, Aygün S, Ata A, Arıcan A. Relationship Between IL-18 and Bone Metastasis in Female Breast Cancer. Turkish Journal of Oncology. 2016;31(1):10-14.

• B4. Unlu A, Nayır E, Ay H, Kırca O, Ozdogan M. Aloe vera and cancer. Turkish Journal of Oncology. 2016;31(2):68-72.

• B5. Vatansever M, Bozkurt FM, Dinc E, Yılmaz EB, Nayir E, Sari AA, Yildirim O, Kara T. Orbital metastasis of multiple myeloma: Case report. Turkish Journal of Ophthalmology. 2016;46:148-150.

• B6. Nayir E, Keskin O. Do We Initiate Chemotherapy at an Early Stage of Hormone-Sensitive Metastatic Prostate Cancer? Turkish Journal of Oncology. 2016;31(4).

C. Articles Published in Other Journals

• C1. Nayır E, Sezgin O, Altıntaş E, Üçbilek E. Pratisyen hekimlerin hepatit B ve hepatit C hakkındaki bilgi düzeyleri. Academic Journal of Gastroenterology. 2012;11(2):58-62.

• C2. Altintas ZM, Altintas E, Sezgin O, Edgunlu TG, Ucbilek E, Nayir E, Barlas IO, Erdal ME. The Effect of Genetic Variations of Methylene Tetrahydropholate Reductase Gene Polymorphisms on Ribavirin-Induced Anemia in Hepatitis C Patients. Journal of Liver: Disease & Transplantation. 2013;2:1.

• C3. Altintas E, Altintas ZM, Sezgin O, Ucbilek E, Nayir E, Erdal ME, Polat A, Orekeci G. Polymorphisms in methylenetetrahydrofolate reductase gene: Their impact on liver steatosis and fibrosis of chronic hepatitis C patients. Open Journal of Gastroenterology. 2014;4:73-80.

• C4. Nayir E, Koyuncu MB, Erdogdu S, Ata A, Yılmaz IA, Arican A. Stiff Person Syndrome in a patient with pancreatic adenocarcinoma: An unusual paraneoplastic syndrome. Journal of Human Rhythm. 2015;1(3):123-126.

• C5. Nayir E, Arican A. Kanser ve insulin direnci, antidiyabetikler ve non-steroidal anti-inflamatuvar ilaçların kanserde etkileri ve kullanımı. Turkey Clinics Journal of Pharmacology – Special Topics. 2015;3(3):36-43.

• C6. Nayir E. A Rarely Seen Hepatic Tumor: Epithelioid hemangioendothelioma. Ulutas Medical Journal. 2016;2(1):59-62.

• C7. Nayir E. Pathogenesis of bone metastasis. Journal of Oncological Science. 2016;1:13-16.

• C8. Tabakan F, Nayir E, Arican A. Clinical and pathological evaluation of histopathological subtypes in patients with non-Hodgkin’s lymphoma. European Research Journal. 2016;2(1):52-61.

• C9. Unlu A, Kirca O, Ozdogan M, Nayir E. High-dose vitamin C and cancer. Journal of Oncological Science. 2016;1:10-12.

• C10. Nayir E, Köşeci T, Arican A. Bilateral meme kanseri ve mide metastazı: Olgu sunumu. Acta Oncologica Turcica. 2016;49(3):232-234.

• C11. Nayir E, Karacabey B, Kirca O, Ozdogan M. Electronic cigarette (e-cigarette). Journal of Oncological Science. 2016;2:16-20.

• C12. Nayir E, Ata A, Erdogdu S, Salman T, Sungur MA, Abali H, Arican A. A snapshot of residents in medical oncology in Turkey: A nationwide survey on profile and key problems. Journal of Oncological Science. 2016;2:21-24.

• C13. Kacan T, Nayir E, Altun A, Kilickap S, Babacan NA, Ataseven H, Kaya T. Antitumor activity of sorafenib on colorectal cancer. Journal of Oncological Science. 2016;2:53-57.

• C14. Nayir E, Ermis E. Chemoradiation of pancreatic carcinoma. Journal of Oncological Science. 2016;2:43-47.

• C15. Karaytug MO, Gurbuz M, Nayir E, Tamam L. Cancer and psychosocial support. Journal of Human Rhythm. 2016;2(3):103-108.

• C16. Bilir C, Yıldız İ, Bilici A, Ucar M, Berk V, Yıldız Y, Yazıcı O, İmamoğlu Gİ, Karadurmuş N, Pilancı KN, Arpacı E, Tanrıverdi Ö, Karcı E, Temiz S, Nayır E, Oktay E, Dal P, Petekkaya İ, Yağmurkaya O, Varım C. Alteration of thyroid functions in patients with renal cell carcinoma treated with tyrosine kinase inhibitors: Turkish population study. Journal of Human Rhythm. 2016;2(4):144-148.

• C17. Nayır E, Cor S, Altintas ZM, Buyukafsar K, Tiftik RN, Ata A, Arican A. Comparative investigation of antitumoral effectiveness of Rho-kinase inhibitor Y-27632, pravastatin and atorvastatin in anaplastic thyroid cancer cell culture. Journal of Oncological Sciences. 2017;3:62-65.

• C18. Tanriverdi O, Barista I, Paydas S, Nayir E, Karakas Y. Oncologists’ Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the Turkish Oncology Group (TOG). Asian Pacific Journal of Cancer Prevention. 2017;18(11):3149-3155.

• C19. Petekkaya E, Petekkaya I, Nayır E, Altındag K. Is there an association between CRP levels and tumor size in breast cancer patients? Journal of Oncological Sciences. 2018;4:106-107.